

Ready to start planning your care? Call us at [800-525-2225](tel:800-525-2225) to make an appointment.

×



Memorial Sloan Kettering
Cancer Center

[About Us](#)
[Sloan Kettering Institute](#)

IMMUNOLOGY PROGRAM

[Research](#)

The Richard O'Reilly Lab

[Education & Training](#)


[Immunology Program](#)
[News & Events](#)

Research
[Open Positions](#)



Richard J. O'Reilly, MD

Our laboratory has as its goal, the elucidation and therapeutic translation of the genetics and immunology of antigen-specific T-cell interactions with virus transformed and malignant cells that affect their function when used for adoptive immunotherapy in immunocompromised cancer patients and recipients of allogeneic hematopoietic or solid organ transplants. We introduced the use of transplant donor derived T-cells for the treatment of EBV lymphomas. Subsequently, we have introduced the use of banked, immediately accessible virus-specific 3rd party T-cells selected on the basis of their HLA restriction and epitope specificity for the treatment of EBV-associated malignancies and drug refractory CMV infections, as well as TCR selected and CAR modified T-cells for hematologic malignancies. To further enhance the efficacy of these T-cell therapies, we are currently evaluating epigenetic modifiers to increase and sustain tumor susceptibility to adoptive T-cell cell therapy and the biological arming of T-cells to enhance their tumor-specific activity.



Publications Highlights

Doubrovina E, Carpenter T, Pankov D, Selvakumar A, Hasan A, O'Reilly RJ. Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted-T-cells with cytotoxic activity against WT-1+ leukemias. *Blood*. 2012 Aug 23;120(8):1633-46.

Dao T, Yan S, Veomett N, Pankov D, Zhou L, Korontsvit T, Scott A, Whitten J, Maslak P, Casey E, Tan T, Liu H, Zakhaleva V, Curcio M, Doubrovina E, O'Reilly RJ, Liu C, Scheinberg DA. Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. *Sci Transl Med*. 2013 Mar 13;5(176):176ra33.

Pai SY, Logan BR, Griffith LM, Buckley RH, Parrott RE, Dvorak CC, Kapoor N, Hanson IC, Filipovich AH, Jyonouchi S, Sullivan KE, Small TN, Burroughs L, Skoda-Smith S, Haight AE, Grizzle A, Pulsipher MA, Chan KW, Fuleihan RL, Haddad E, Loechelt B, Aquino VM, Gillio A, Davis J, Knutsen A, Smith AR, Moore TB, Schroeder ML, Goldman FD, Connelly JA, Porteus MH, Xiang Q, Shearer WT, Fleisher TA, Kohn DB, Puck JM, Notarangelo LD, Cowan MJ, O'Reilly RJ. Transplantation outcomes for severe combined immunodeficiency, 2000-2009. *N Engl J Med*. 2014;371(5):434-446.

Zhao Q, Ahmed M, Tassev DV, Hasan A, Kuo TY, Guo HF, O'Reilly RJ, Cheung NK. Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential. *Leukemia*. 2015 May 19. Epub ahead of print.

Koehne G, Hasan A, Doubrovina E, Prockop S, Tyler E, Wasilewski G, O'Reilly R. Immunotherapy with Donor T-cells Sensitized with Overlapping Pentadecapeptides for Treatment of Persistent Cytomegalovirus Infection or Viremia. [Biol Blood Marrow Transplant](#). 2015 Sep;21(9):1663-78.

[View All Publications](#)

People



Richard J. O'Reilly, MD

Physician-scientist Richard O'Reilly investigates the genetic disparities and cellular interactions between donor and host that affect allogeneic hematopoietic cell transplantation.

MD, University of Rochester School of Medicine

oreillyr@mskcc.org

Email Address

[212-639-5957](tel:212-639-5957)

Office Phone


[View physician profile](#)

Physician profile

Members

Research Technician

Research Assistant, Sr



Keith
Price
Research Technician



Annamalai
Selvakumar
Assistant Lab member



Teresa Vizconde
Research Technician

Lab Affiliations
+

Get in Touch

✉ oreillyr@mskcc.org
Lab Head Email

☎ [212-639-5957](tel:212-639-5957)
Office Phone

☎ [646-888-2366](tel:646-888-2366)
Lab Phone

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Richard J. O'Reilly discloses the following relationships and financial interests:

Atara Biotherapeutics
Intellectual Property Rights
Damon Runyon Cancer Research Foundation
Fiduciary Role / Position

Ronald McDonald House New York
Fiduciary Role / Position

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies [here](#). For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.

[View all disclosures](#) →

About Us

Overview

Leadership

Administration

History

Contact Us

Research

Overview

Research programs

Research labs

[Core facilities & resources](#)

▾ Education & Training

[Overview](#)

[Postdoctoral training](#)

[Gerstner Sloan Kettering Graduate School](#)

[Joint graduate programs](#)

[Programs for college & high school students](#)

▾ News & Events

[Overview](#)

[Seminars & events](#)

▾ Open Positions

[Overview](#)

[Faculty positions](#)

[Postdoctoral positions](#)

[Communication preferences](#)

[Cookie preferences](#)

[Legal disclaimer](#)

[Accessibility Statement](#)

[Privacy policy](#)

[Public notices](#)

© 2024 Memorial Sloan Kettering Cancer Center